Posted On: 04/11/2016 11:41:01 AM
Post# of 405
THIS IS A ONCE IN A LIFETIME OPPORTUNITY .The MOST underpriced Stock and with lowest Market Cap (laughable $4 M) out there which awaiting FDA approval .
13 Marketed Products/ MEGA FDA approval for their biggest Drug Fluticare this Q / NYSE Listing in 2016
FDA approval of FlutiCare expected this Quarter could push this undiscovered low float and heavily underpriced stock to minimum $0.80-$1 .
Market Cap : $3.9 M
Cash $2M untill mid 2017
Price: $0.058
Shares out: 67.6 M
Top Shareholders
http://data.cnbc.com/quotes/INNV/tab/8
Total Number of Shares Held 34.8M
Innovus Pharma Enters $1 Billion Worldwide Nasal Steroid Market with the Acquisition of FlutiCare(TM) (Fluticasone Propionate Nasal) Over The Counter ("OTC"
Rights from Novalere
http://finance.yahoo.com/news/innovus-pharma-...00968.html
Innovus Pharma expects that the ANDA may be approved by the end of 2015 or in the first half of 2016 by the U.S. Food and Drug Administration ("FDA" .
- FlutiCare(TM) is a nasal spray in the form that has been the #1 prescribed nasal spray to patients in the US for more than five consecutive years
- More than 40 million units of FlutiCare(TM) nasal spray product form have been sold in the U.S. in 2014
Innovus Pharma CEO Provides Shareholder Update
http://finance.yahoo.com/news/innovus-pharma-...00392.html
Emerging Markets Report: A Growing Presence in a Fast-Growing Market...Mar 16, 2016
http://www.otcmarkets.com/stock/INNV/news?id=127538
Why is Innovus Pharma a good Investment
1.Innovus Pharma has 13 commercial products
2.They started generating revenues from their sales
3.Has partners in 30 countries with over $500M in signed sales milestones
4 Has a large respiratory asset (FlutiCare) for allergic rhinitis awaiting FDA approval
5.Might be a potential target for acquisition in the near future due to their undervalued market cap
By far the biggest revenue generating product for Innovus will be FlutiCare if the OTC ANDA is approved by the FDA as it goes head to head against Flonase from GSK with a better delivery form which is the most used form in the prescription market. The Company announced over 36,000 vendors of record in the US which would give them an immediate placement in most of the retail stores in the US and immediate sales. The usual market retention of an Rx to OTC share of the market is about 15%. The current prescription form of the product is estimated to make close to $300M a year in revenues according to the Company’s last presentation at the Marcum Conference .
13 Marketed Products/ MEGA FDA approval for their biggest Drug Fluticare this Q / NYSE Listing in 2016
FDA approval of FlutiCare expected this Quarter could push this undiscovered low float and heavily underpriced stock to minimum $0.80-$1 .
Market Cap : $3.9 M
Cash $2M untill mid 2017
Price: $0.058
Shares out: 67.6 M
Top Shareholders
http://data.cnbc.com/quotes/INNV/tab/8
Total Number of Shares Held 34.8M
Innovus Pharma Enters $1 Billion Worldwide Nasal Steroid Market with the Acquisition of FlutiCare(TM) (Fluticasone Propionate Nasal) Over The Counter ("OTC"
Rights from Novalere http://finance.yahoo.com/news/innovus-pharma-...00968.html
Innovus Pharma expects that the ANDA may be approved by the end of 2015 or in the first half of 2016 by the U.S. Food and Drug Administration ("FDA"
. - FlutiCare(TM) is a nasal spray in the form that has been the #1 prescribed nasal spray to patients in the US for more than five consecutive years
- More than 40 million units of FlutiCare(TM) nasal spray product form have been sold in the U.S. in 2014
Innovus Pharma CEO Provides Shareholder Update
http://finance.yahoo.com/news/innovus-pharma-...00392.html
Emerging Markets Report: A Growing Presence in a Fast-Growing Market...Mar 16, 2016
http://www.otcmarkets.com/stock/INNV/news?id=127538
Why is Innovus Pharma a good Investment
1.Innovus Pharma has 13 commercial products
2.They started generating revenues from their sales
3.Has partners in 30 countries with over $500M in signed sales milestones
4 Has a large respiratory asset (FlutiCare) for allergic rhinitis awaiting FDA approval
5.Might be a potential target for acquisition in the near future due to their undervalued market cap
By far the biggest revenue generating product for Innovus will be FlutiCare if the OTC ANDA is approved by the FDA as it goes head to head against Flonase from GSK with a better delivery form which is the most used form in the prescription market. The Company announced over 36,000 vendors of record in the US which would give them an immediate placement in most of the retail stores in the US and immediate sales. The usual market retention of an Rx to OTC share of the market is about 15%. The current prescription form of the product is estimated to make close to $300M a year in revenues according to the Company’s last presentation at the Marcum Conference .
(0)
(0)
